Pesquisar
Bristol-Myers Squibb Co
BMYAdicionar à lista de desejos
59.365USD
+1.785+3.10%
Fechamento 07/13, 16:00（ET）Cotações atrasadas em 15 min
121.22BValor de mercado
16.62P/L TTM
Mais detalhes de Bristol-Myers Squibb Co Empresa
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Informações de Bristol-Myers Squibb Co
Código da empresaBMY
Nome da EmpresaBristol-Myers Squibb Co
Data de listagemMar 17, 1980
CEOBoerner (Christopher S)
Número de funcionários34100
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 17
EndereçoRoute 206 And Province Line Road
CidadePRINCETON
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal08543
Telefone16092524621
Sitehttps://www.bms.com
Código da empresaBMY
Data de listagemMar 17, 1980
CEOBoerner (Christopher S)
Executivos da empresa Bristol-Myers Squibb Co
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Mr. Michael R. (Mike) McMullen
Mr. Michael R. (Mike) McMullen
Independent Director
Independent Director
1.00K
--
Mr. Peter J. (Pete) Arduini
Mr. Peter J. (Pete) Arduini
Independent Director
Independent Director
--
--
Mr. Theodore R. Samuels, II
Mr. Theodore R. Samuels, II
Lead Independent Director
Lead Independent Director
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Bristol-Myers Squibb Co?
Os cinco principais acionistas de Bristol-Myers Squibb Co são: Dr. Christopher S. (Chris) Boerner, Ph.D.
Quantas instituições possuem ações da Bristol-Myers Squibb Co (BMY)?
Em 2026Q1, 4176 instituições possuíam ações da Bristol-Myers Squibb Co, com valor de mercado aproximado de 1.72B, representando 84.35% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -11351598.00.
Qual é a maior fonte de receita da Bristol-Myers Squibb Co?
Em 2026Q1, o segmento de negócios Eliquis gerou a maior receita para Bristol-Myers Squibb Co, totalizando 14.44B e representando 29.97% da receita total.